新光药业 (300519.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	260.6M	265.4M	267.7M	270.4M	351.5M
Cost of Revenue	151.9M	162.5M	177.1M	158.8M	169.2M
Gross Profit	108.7M	102.9M	90.5M	111.6M	182.3M
Operating Expenses
R&D Expense	11.9M	13.3M	12.6M	15.1M	15.5M
SG&A Expense	—	—	—	—	—
General & Admin Expense	17.7M	18.4M	17.5M	17.9M	17.3M
Selling & Marketing Expense	18.5M	20.1M	24.4M	26.5M	33.7M
Other Expenses	—	—	—	—	—
Total Operating Expenses	49.3M	45.8M	40.3M	45.0M	61.0M
Cost and Expenses	201.2M	208.3M	217.5M	203.8M	230.3M
Operating Income (EBIT)	67.4M	64.9M	57.3M	74.1M	126.6M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	65.7M	63.4M	57.0M	73.2M	125.6M
Income Tax Expense	9.7M	9.2M	6.6M	8.8M	16.8M
Bottom Line
Net Income	56.0M	54.2M	50.4M	64.4M	108.8M
Earnings from Cont. Ops	56.0M	54.2M	50.4M	64.4M	108.8M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	56.0M	54.2M	50.4M	64.4M	108.8M
Per Share
Basic EPS	CN¥0.34	CN¥0.34	CN¥0.31	CN¥0.40	CN¥0.68
Diluted EPS	CN¥0.34	CN¥0.34	CN¥0.31	CN¥0.40	CN¥0.68
Revenue Per Share	CN¥1.58	CN¥1.66	CN¥1.65	CN¥1.68	CN¥2.20
Shares
Basic Shares Outstanding	164.8M	159.4M	162.5M	160.9M	160.0M
Diluted Shares Outstanding	164.8M	159.4M	162.5M	160.9M	160.0M
Profitability Metrics
EBITDA	—	79.6M	72.3M	88.9M	140.7M
D&A	—	14.7M	14.9M	14.8M	14.1M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026